Ardelyx, AAKP, and NMQF sue HHS and CMS over XPHOZAH inclusion in ESRD PPS, claiming it harms patient choice and access.

Ardelyx, AAKP, and NMQF have filed a lawsuit against the U.S. Department of Health and Human Services and CMS, claiming that including XPHOZAH and other oral-only phosphate-lowering therapies in the End-Stage Renal Disease Prospective Payment System (ESRD PPS) will negatively impact patient choice and access to essential medications. The lawsuit seeks to prevent CMS from proceeding with its plan to include XPHOZAH in the ESRD PPS and eliminate coverage under Medicare Part D, starting on January 1, 2025.

July 17, 2024
5 Articles

Further Reading